Was the Vaccine Taskforce a launchpad for gene therapies, now being catapulted into outerspace?
Looks very much like it, but who knows?!
Recap on UK Government’s excursion into gene therapy
Yesterday, I added to a list of posts covering the topic of how gene therapies became UK Government’s top priority in establishing itself as a world power in pharma R&D, post Brexit:
UK Government's infatuation with gene therapy goes back a long way—it's not healthy
To sum it up in simple terms, in 2013, I was commissioned by the manufacturer of the AstraZeneca vaccine, Oxford Biomedica (not AZ!), to spearhead a bid for a Government funding call. It required skills in advanced manufacturing supply chain management in life sciences, which I have.
This is the full account:
The bid was successful, raising £7.1 million for Oxford Biomedica.
It attracted enormous attention from Government, especially since Government funded Innovate UK was part of the bid, in the form of the Cell and Gene Therapy Catapult (CGTC).
The CGTC has carried on tryi…